- Home
- WGSWW vs SKYW Comparison
WGSWW vs SKYW Comparison
Compare WGSWW & SKYW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WGSWW
- SKYW
- Stock Information
- Founded
- WGSWW 2017
- SKYW 1972
- Country
- WGSWW United States
- SKYW United States
- Employees
- WGSWW 1000
- SKYW N/A
- Industry
- WGSWW Retail: Computer Software & Peripheral Equipment
- SKYW Air Freight/Delivery Services
- Sector
- WGSWW Technology
- SKYW Consumer Discretionary
- Exchange
- WGSWW Nasdaq
- SKYW Nasdaq
- Market Cap
- WGSWW N/A
- SKYW N/A
- IPO Year
- WGSWW N/A
- SKYW N/A
- Fundamental
- Price
- WGSWW $0.05
- SKYW $99.54
- Analyst Decision
- WGSWW
- SKYW Strong Buy
- Analyst Count
- WGSWW 0
- SKYW 3
- Target Price
- WGSWW N/A
- SKYW $120.67
- AVG Volume (30 Days)
- WGSWW 36.6K
- SKYW 371.2K
- Earning Date
- WGSWW 02-18-2025
- SKYW 04-24-2025
- Dividend Yield
- WGSWW N/A
- SKYW N/A
- EPS Growth
- WGSWW N/A
- SKYW 219.12
- EPS
- WGSWW N/A
- SKYW 8.74
- Revenue
- WGSWW $305,450,000.00
- SKYW $3,672,761,000.00
- Revenue This Year
- WGSWW N/A
- SKYW $10.89
- Revenue Next Year
- WGSWW N/A
- SKYW $4.14
- P/E Ratio
- WGSWW N/A
- SKYW $11.37
- Revenue Growth
- WGSWW 50.79
- SKYW 20.53
- 52 Week Low
- WGSWW $0.17
- SKYW $64.61
- 52 Week High
- WGSWW $0.21
- SKYW $135.57
- Technical
- Relative Strength Index (RSI)
- WGSWW N/A
- SKYW 68.28
- Support Level
- WGSWW N/A
- SKYW $91.50
- Resistance Level
- WGSWW N/A
- SKYW $101.54
- Average True Range (ATR)
- WGSWW 0.00
- SKYW 3.50
- MACD
- WGSWW 0.00
- SKYW 1.56
- Stochastic Oscillator
- WGSWW 0.00
- SKYW 88.61
About WGSWW GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.